ARTICLE | Clinical News
GLPG2222: Phase I data
June 27, 2016 7:00 AM UTC
A double-blind, placebo-controlled, Belgian Phase I trial in about 40 healthy volunteers showed that single ascending doses of up to 800 mg oral GLPG2222 and once-daily ascending doses of up to 600 mg...